Costunolide being a sesquiterpene lactone, is known to have anticancer properties. The present study investigated the anticancer effects of costunolide against the H1299 human non-small-cell lung cancer (NSCLC) cell line. Inhibition of cell viability by costunolide was assessed via a MTT assay. Furthermore, the apoptotic rate was detected using Annexin V/propidium iodide labeling. A colony forming cell assay was performed to investigate the antiproliferative effects of costunolide. Wound healing and Transwell assays were performed to determine the inhibitory effects of costunolide on migration and invasion, respectively. Western blot analysis was undertaken to determine protein expression, and reverse transcription-quantitative PCR was performed to assess mRNA expression levels. The results demonstrated that costunolide inhibited the viability of H1299 cells, with a half maximal inhibitory concentration value of 23.93±1.67 µM and induced cellular apoptosis in a dose-dependent manner. Furthermore, the colony formation, migrative and invasive abilities of the H1299 cells were inhibited in a dose-or time-dependent manner. The protein expression levels of E-cadherin increased and those of N-cadherin decreased following treatment with costunolide, which suggested that costunolide inhibited epithelial-to-mesenchymal transition. The mRNA levels of B-Raf, E-cadherin, N-cadherin, integrins α2 and β1, as well as matrix metalloproteinases 2 were also found to be regulated costunolide. These findings indicate the potential of costunolide in the treatment of NSCLC.
Introduction
Lung cancer is one of the most common malignancies worldwide, of which 80-85% of all cases are non-small-cell lung cancer (NSCLC) (1) . Clinically, very few patients with NSCLC are diagnosed at an early stage, when surgical resection is curative (1, 2) . Thus, conventional chemotherapy and radiation therapy remain the mainstay of the treatment for lung cancer, and the development of novel anticancer drugs is critical.
Plants have long been considered a rich source of bioactive natural products, some of which exhibit potent activity as potential anticancer agents (3) (4) (5) (6) (7) . Costunolide is a sesquiterpene lactone (Fig. 1A) , which is extracted from various plant species, including genus Saussurea, Aucklandia and Inula (8) (9) (10) . Costunolide exhibits a series of pharmacological activities, including anti-inflammatory (11) , anti-allergic (12) and antimicrobial (13) effects. Notably, potent anticancer properties of costunolide have been identified in lung cancer and leukemia (14, 15) .
Costunolide has been demonstrated to inhibit cell proliferation, induce apoptosis and inhibit angiogenesis in lung cancer cells and leukemia cells (16) (17) (18) . However, the molecular mechanism by which costunolide inhibits tumor metastasis remains unclear. Thus, the present study aimed to investigate the in vitro antimetastatic effect of costunolide in the H1299 NSCLC cell line and assess the underlying molecular
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mechanisms. The results may be used as experimental evidence to support the role of costunolide against NSCLC.
Materials and methods
Cell culture and reagents. The H1299 human NSCLC cell line was purchased from iCell Bioscience Inc. and authenticated via short-tandem repeat profiling. Colony forming cell (CFC) assay. H1299 cells were split and seeded into 12-well plates at a density of 400 cells/plate. Once clones of ~30 cells were formed, they were treated with 24.0 µM costunolide for 0, 24, 48, 72 and 96 h. In another experiment, cells were treated with varying concentrations of costunolide (0, 6.0, 12.0, 24.0 and 48.0 µM) for 48 h. The wells were washed with PBS three times, fixed with analytically pure methanol (Shanghai Titan Scientific Co., Ltd.) for 30 min and then stained with 0.05% crystal violet. After staining for 15 min at room temperature, crystal violet was removed and the wells were cleaned using running water. Plates were photographed after drying. All experiments were performed in triplicate.
Wound healing assay. H1299 cells were digested using trypsin and resuspended in serum-free medium. Cells were seeded into 6-well plates and allowed to reach 100% confluence overnight. Subsequently, linear wounds were scratched in the cell monolayer using a pipette tip and the wounded cell layer was washed three times with PBS to remove detached cells. Cells were incubated with 0, 12.0, 24.0 and 48.0 µM concentrations of costunolide, and wounds were observed and captured using a light microscope (x40) after 0, 24 and 48 h of incubation, respectively. Cell motility was determined according to the percentage of the repaired wound area. The percentage wound closure was calculated as follows: Migrated cell surface area/total surface area x100 (19) .
Invasion assay. The insert of a Transwell apparatus (Corning Inc.) was pre-coated with 25% Matrigel (Corning Inc.), which was diluted with serum-free RPMI-1640. H1299 cells were seeded in the upper chamber of the Transwell apparatus at a density of 8x10 3 cells/chamber, in 200 µl serum-free RPMI-1640 medium containing 0, 12.0, 24.0 and 48.0 µM concentrations of costunolide. A total of 600 µl RPMI-1640 medium, containing 10% FBS was added to the lower chamber, which acted as a chemoattractant. After 24 and 48 h, cells that migrated into the lower chamber were fixed with analytically pure methanol and stained with 0.05% crystal violet at room temperature for 30 min. Cells on the top layer were removed using a cotton swab, and images of the migrated cells were captured using a light microscope (x200). A total of nine random fields were acquired to quantify attached and migrated cells. ImageJ software version 1.51j8 (http://imagej. nih.gov/ij) was used to quantify the cell number. Cell counts were expressed as the mean number of cells/field of view (20) .
Reverse transcription-quantitative (RT-q)PCR. Total RNA was extracted from H1299 cells following treatment with 0, 12.0, 24.0 and 48.0 µM concentrations of costunolide for 6 and 12 h at room temperature, using TRIzol ® reagent (Thermo Fisher Scientific, Inc.), according to the manufacturer's instructions. Total RNA was reverse transcribed into cDNA using the PrimeScript™ RT Master mix (Takara Bio, Inc.), according to the manufacturer's instructions. The forward and reverse primer sequences were designed by Takara Bio, Inc. (Table SI) , in order to detect the expression levels of B-Raf, integrin α2, integrin β1, matrix metalloproteinase 2 (MMP2), N-cadherin and E-cadherin. qPCR was subsequently performed using SYBR ® Premix Ex Taq™ (Tli RNase H Plus; Takara Bio, Inc.) and QuantStudio 5 (Thermo Fisher Scientific, Inc.), according to the manufacturer's instructions. The RT-qPCR program was set as initial denaturation at 95˚C for 30 sec; then 40 reaction cycles were followed by denaturation at 95˚C for 5 sec, annealing at 60˚C for 34 sec, and then elongation at 72˚C for 30 sec. mRNA expression levels were quantified using the 2 -ΔΔCq method and normalized to the internal reference gene GAPDH (21) . 
Results
Costunolide exerts a notable inhibitory effect against H1299 cells. The inhibition of cell viability by costunolide was assessed via MTT assay. Costunolide was demonstrated to inhibit the viability of H1299 cells, with an IC 50 value of 23.93±1.67 µM. The inhibition occurred in a dose-dependent manner (Fig. 1B) .
Costunolide induces apoptosis in H1299 cells. H1299 cells were treated with 0, 12.0, 24.0 and 48.0 µM of costunolide for 48 h, in order to investigate whether the antitumor effect of costunolide against H1299 cells was mediated via apoptosis. The apoptotic rate was assessed via flow cytometry, based on Annexin V and PI staining. The apoptotic rates were as follows: 6.26±1.08, 7.94±1.49, 10.01±1.29 and 22.68±3.56% for 0, 12.0, 24.0 and 48.0 µM costunolide, respectively. The results showed that the apoptotic rate between the control and 24.0 µM group was significantly different, as was that between the 24.0 and 48.0 µM groups (Fig. 2) .
Costunolide decreases colony formation of H1299 cells. The CFC assay was performed to further investigate the antiproliferative effects of costunolide. The results demonstrated that incubation of H1299 cells with 6.0, 12.0, 24.0 and 48.0 µM costunolide for 48 h, and with 24.0 µM costunolide for 0, 24, 48, 72 and 96 h decreased the colony formation of H1299 cells in a dose-and time-dependent manner, as revealed by reductions in the colony numbers and sizes ( Fig. 3) .
Costunolide decreases the migrative ability of H1299 cells.
Wound healing assays were performed to assess the effect of costunolide on the migrative ability of H1299 cells. H1299 cells were treated with 12.0, 24.0 and 48.0 µM costunolide for 24 h, and the mobility ratios with respect to the untreated control were as follows: 16.16±1.39, 12.35±2.32 and 5.34±0.88%, respectively. Following treatment of H1299 cells with 12.0, 24.0 and 48.0 µM of costunolide for 48 h, the mobility ratios were as follows: 39.89±3.85, 32.90±3.04 and 18.49±1.62%, respectively (Fig. 4) . These results suggest that costunolide markedly inhibits H1299 cell migration in a dose-dependent manner.
Costunolide decreases the invasive ability of H1299 cells.
Invasion is another process associated with cancer proliferation and metastasis (22) . Transwell assays were performed to assess the effect of costunolide on the invasive ability of H1299 cells. Consistent with the results of the migration assay, costunolide significantly inhibited the invasive ability of H1299 cells. Following the treatment of H1299 cells with 12.0, 24.0 and 48.0 µM costunolide for 48 h, and with 24.0 µM costunolide for 24 and 48 h, the number of invaded cells significantly decreased compared with the untreated control ( Fig. 5) . These results indicate that costunolide decreases H1299 cell invasion in a dose-and time-dependent manner. Costunolide regulates metastasis-and proliferationassociated mRNA expression. RT-qPCR analysis was performed to determine whether the antiproliferative, antimigration and anti-invasive properties of costunolide were associated with changes in specific mRNA levels. Following the treatment of H1299 cells with 12.0, 24.0 and 48.0 µM costunolide for 6 h, the mRNA expression levels of E-cadherin were demonstrated to be upregulated (Fig. 6A) , and the mRNA expression levels of N-cadherin, integrin α2, integrin β1, MMP2 and B-Raf were downregulated compared with the untreated control in a dose-dependent manner (Fig. 6B-F) . Consistent with these results, treatment of H1299 cells with the same concentration gradient of costunolide for 12 h regulated the same mRNA levels in a dose-dependent manner (Fig. 6) .
Costunolide regulates epithelial-to-mesenchymal transition (EMT)-associated protein expression. EMT is considered to be a key process in cancer metastasis, in which E-cadherin and N-cadherin are markers (23) . In order to investigate whether costunolide is able to inhibit the EMT of H1299 cells, western blotting was performed to detect the protein expression levels of E-cadherin and N-cadherin. Following treatment of H1299 cells with 12.0, 24.0 and 48.0 µM costunolide for 48 h, the protein expression levels of E-cadherin increased, while those of N-cadherin decreased compared with those in the untreated control (Fig. 7) . These results suggest that costunolide has the ability to significantly inhibit the EMT of H1299 cells.
Discussion
Costunolide is a sesquiterpene lactone (24) , which has been reported to exert antiproliferative effects against a wide range of cancer cells, including gastric cancer (25) , leukemia (26), colorectal cancer (27) and lung cancer (16) . The results of the present study demonstrated that costunolide inhibited the proliferation of H1299 NSCLC cells, with an IC 50 value of 23.93±1.67 µM. These results are consistent with the findings of a previous study on MDA-MB-231 cells (28) . Apoptosis is a type of programmed cell death designed to eliminate redundant, damaged or even infected cells in order to maintain homeostasis (29) . The apoptotic effect of costunolide against cancer cells has previously been reported (9, 16) . The results of the present study demonstrated that costunolide induced a dose-dependent increase in the apoptotic ratio of H1299 cells, indicating the key role of apoptosis in the antiproliferative effects of costunolide. The CFC assay indicated that costunolide decreased colony formation by H1299 cells, in an apparently dose-and time-dependent manner. B-Raf is one of the most commonly mutated proto-oncogenes, which plays a key role in the development of several types of cancer of high clinical impact (30) . The results of the present study demonstrated that B-Raf mRNA expression levels were dose-dependently downregulated by costunolide in H1299 lung cancer cells.
Metastasis involves a series of consecutive events, in which cancer cells migrate, invade and eventually colonize distant regions (31) . The results of the present study demonstrated that costunolide inhibited cancer migration in a dose-dependent manner, and invasion in a dose-and time-dependent manner.
EMT, a biological process in which epithelial features are lost while mesenchymal features are acquired (22) , is closely associated with the migration and invasion of cancer cells. E-cadherin is considered to be an epithelial marker and N-cadherin is a key mesenchymal marker of EMT (23) . In the present study, the RT-qPCR results demonstrated that the underlying molecular mechanism of action of costunolide may involve regulation of the mRNA expression of cadherin. Increased E-cadherin protein expression levels and decreased N-cadherin protein expression levels in the H1299 lung cancer cells confirmed that costunolide has the potential to inhibit EMT in vitro. In the present study, the mRNA expression levels of integrins α2 and β1 were detected. Integrins are adhesive receptors located on the cell surface, which mediate cell adhesion (32) . Furthermore, MMPs induce cancer cell migration via degradation of the extracellular matrix (33). In the present study, costunolide dose-dependently downregulated the mRNA expression levels of integrins α2 and β1, as well as MMP2 in H1299 cells, which indicated the inhibitory potential of costunolide against NSCLC metastasis. It remains unclear how costunolide influences other genes associated with EMT. In future studies, the present research team will use RNA sequencing or microarrays to observe the landscape gene expression changes caused by costunolide and confirm the efficacy of costunolide in the treatment of NSCLC. Also, determining the efficacy of costunolide in vivo will help to elucidate the anticancer activity of costunolide. The potential antiproliferative, antimigration and anti-invasive molecular mechanisms of costunolide revealed in the present study are summarized in Fig. 8 .
In conclusion, the present study revealed the antiproliferation, apoptosis-inducing, antimigration and anti-invasion effects of costunolide against H1299 human NSCLC cells. The results suggest that costunolide may have the potential to inhibit the EMT of H1299 cells in vitro.
